Managing Hidradenitis Suppurativa with Biologics and Small Molecule Inhibitors
Victoria Fang1, Radhika Gupta2, Robert G Micheletti3
1Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
"Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a significant quality-of-life impact. In addition to the 2 drugs approved by the Food and Drug Administration for HS, adalimumab and secukinumab, several other biologic and small molecule inhibitors are used off-label or are in clinical trials. A systematic and evidence-based approach using these and other therapies-considering patient comorbidities, response to therapy, dose adjustment, and frequent troubleshooting-is required. In this article, we review the latest evidence supporting anti-inflammatory biologic and small molecule therapies for HS and provide a practical, algorithmic approach to management incorporating experience and expert opinion."
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents


